AIM: To evaluated the therapeutic and prophylactic effect of thalidomide on 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. Thalidomide has been reported to downregulate the expression of tumor necrosis factor alpha (TNF-alpha), IL-12, and vascular endothelial growth factor (VEGF), hallmarks of intestinal inflammation in Crohnos disease (CD). METHODS: Male Wistar rats were divided in five groups of ten animals each. Four groups received a rectal infusion of TNBS in ethanol. The first group was sacrificed 7 d after colitis induction. The second and third groups received either thalidomide or placebo by gavage and were sacrificed at 14 d. The fourth group received thalidomide 6 h before TNBS administration, and was sacrificed 7 d after induction. The fifth group acted as the control group and colitis was not induced. Histological inflammatory scores of the colon were performed and lamina propria CD4+ T cells, macrophages, and VEGF+ cells were detected by immunohistochemistry. TNF-alpha and IL-12 were quantified in the supernatant of organ cultures by ELISA. RESULTS: Significant reduction in the inflammatory score and in the percentage of VEGF+ cells was observed in the group treated with thalidomide compared with animals not treated with thalidomide. Both TNF-alpha and IL-12 levels were significantly reduced among TNBS induced colitis animals treated with thalidomide compared with animals that did not receive thalidomide. TNF-alpha levels were also significantly reduced among the animals receiving thalidomide prophylaxis compared with untreated animals with TNBS-induced colitis. Intestinal levels of TNF-alpha and IL-12 were significantly correlated with the inflammatory score and the number of VEGF+ cells. CONCLUSION: Thalidomide significantly attenuates TNBS-induced colitis by inhibiting the intestinal production of TNF-alpha, IL-12, and VEGF. This effect may support the use of thalidomide as an alternate approach in selected patients with CD.
AIM: To evaluated the therapeutic and prophylactic effect of thalidomide on 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. Thalidomide has been reported to downregulate the expression of tumor necrosis factor alpha (TNF-alpha), IL-12, and vascular endothelial growth factor (VEGF), hallmarks of intestinal inflammation in Crohnos disease (CD). METHODS: Male Wistar rats were divided in five groups of ten animals each. Four groups received a rectal infusion of TNBS in ethanol. The first group was sacrificed 7 d after colitis induction. The second and third groups received either thalidomide or placebo by gavage and were sacrificed at 14 d. The fourth group received thalidomide 6 h before TNBS administration, and was sacrificed 7 d after induction. The fifth group acted as the control group and colitis was not induced. Histological inflammatory scores of the colon were performed and lamina propria CD4+ T cells, macrophages, and VEGF+ cells were detected by immunohistochemistry. TNF-alpha and IL-12 were quantified in the supernatant of organ cultures by ELISA. RESULTS: Significant reduction in the inflammatory score and in the percentage of VEGF+ cells was observed in the group treated with thalidomide compared with animals not treated with thalidomide. Both TNF-alpha and IL-12 levels were significantly reduced among TNBS induced colitis animals treated with thalidomide compared with animals that did not receive thalidomide. TNF-alpha levels were also significantly reduced among the animals receiving thalidomide prophylaxis compared with untreated animals with TNBS-induced colitis. Intestinal levels of TNF-alpha and IL-12 were significantly correlated with the inflammatory score and the number of VEGF+ cells. CONCLUSION:Thalidomide significantly attenuates TNBS-induced colitis by inhibiting the intestinal production of TNF-alpha, IL-12, and VEGF. This effect may support the use of thalidomide as an alternate approach in selected patients with CD.
Authors: J Spalinger; H Patriquin; M C Miron; G Marx; D Herzog; J Dubois; M Dubinsky; E G Seidman Journal: Radiology Date: 2000-12 Impact factor: 11.105
Authors: T Parrello; G Monteleone; S Cucchiara; I Monteleone; L Sebkova; P Doldo; F Luzza; F Pallone Journal: J Immunol Date: 2000-12-15 Impact factor: 5.422
Authors: Walter E Cromer; J Michael Mathis; Daniel N Granger; Ganta V Chaitanya; J Steven Alexander Journal: World J Gastroenterol Date: 2011-02-07 Impact factor: 5.742
Authors: Bopaiah P Cheppudira; Beatrice M Girard; Susan E Malley; Kristin C Schutz; Victor May; Margaret A Vizzard Journal: Am J Physiol Renal Physiol Date: 2008-07-16
Authors: Kirstin Reinecke; Sevgi Eminel; Franziska Dierck; Wibke Roessner; Sabine Kersting; Ansgar Michael Chromik; Olga Gavrilova; Ale Laukevicience; Ivo Leuschner; Vicki Waetzig; Philip Rosenstiel; Thomas Herdegen; Christian Sina Journal: PLoS One Date: 2012-03-13 Impact factor: 3.240
Authors: Melissa N van Tok; Nimman Satumtira; Martha Dorris; Desirée Pots; Gleb Slobodin; Marleen G van de Sande; Joel D Taurog; Dominique L Baeten; Leonie M van Duivenvoorde Journal: Front Immunol Date: 2017-08-07 Impact factor: 7.561
Authors: Sabine Kersting; Volker Behrendt; Jonas Kersting; Kirstin Reinecke; Christoph Hilgert; Ingo Stricker; Thomas Herdegen; Monika S Janot; Waldemar Uhl; Ansgar M Chromik Journal: J Inflamm Res Date: 2013-05-03